Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8836904 | Surgery | 2018 | 7 Pages |
Abstract
Despite healthcare provider bias, there seems to be no nutritional or perioperative benefit for enteral access before neoadjuvant chemoradiation for esophageal malignancy. Patients with esophageal malignancy should therefore proceed to appropriate neoadjuvant and surgical therapy with enteral access performed during definitive resection or reserved for those with frank obstruction on endoscopy.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Thomas K. Jenkins, Alexandra N. Lopez, George A. Sarosi, Kfir Ben-David, Ryan M. Thomas,